Important Safety Information:
CONTRAINDICATIONS: ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.
WARNINGS AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products.Full Important Safety Information
MyELOCTATE™ can assist with the prior authorization process for ELOCTATE and provide support all the way until your patients receive their treatment
Questions? Call 1-855-MyELOCTATE (1-855-693-5628), Monday through Friday, 8 AM to 8 PM ET, or request a visit with a MyELOCTATE Representative.
*Those with federal and state government insurance, such as Medicare, Medicaid, or TRICARE®, are not eligible. Eligibility criteria apply. Have your patients contact their MyELOCTATE™ Coordinator to see if they are eligible for any of these programs. Sanofi Genzyme reserves the right to modify or discontinue these programs at any time. TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved. Any prior authorization must be completed by a patient's HCP. MyELOCTATE™ will not assist in completion or submission of these forms.
Sanofi Genzyme has joined with MicroHealth in supporting patients and healthcare providers to help manage hemophilia.
Request a visit with a MyELOCTATE Representative if you need additional help with ELOCTATE payer coding.